1. Congestive Heart Failure: http://www.heartcenteronline.com/healthyliving/profile/index.cfm?hcoref=pu2

 

2.Morisco C, et al. Effect of coenzyme Q10 therapy in patients with congestive heart failure: a long-term multicenter randomized study. Clin Investig. 1993;71(8 Suppl):S134-6.
 

3 Mortensen SA, et al. Coenzyme Q10: clinical benefits with biochemical correlates suggesting a scientific breakthrough in the management of chronic heart failure. Int J Tissue React. 1990;12(3):155-62.
 

4. Baggio E et al., Italian multicenter study on the safety and efficacy of coenzyme Q10 as adjunctive therapy in heart failure. CoQ10 Drug Surveillance Investigators. Clin Investig 1993 71 (8 Suppl): S145-9

 

5. Ishiyama T et al., A clinical study of the effect of coenzyme Q on congestive heart failure. Jpn Heart J 1976 (17):32

 

6. Pizzorno JE and Murray MT, eds. Encyclopedia of Natural Medicine, revised 2nd edition, CA: Prima Publishing, 1998: 504-506.

 

7. Siembab L, et al. Current views on the clinical significance of coronary artery spasm. Przegl Lek. 1995;52(8):395-9.
 

8. Gottlieb SS et al. "Prognostic importance of serum magnesium concentration in patients with congestive heart failure, J Am Coll Cardiol 1990 (16): 827-31.

 

9. Gottlieb SS. Importance of magnesium in congestive heart failure. Am J Cardiol 1989 (63): 39G-42G.

 

10. McLean RM. Magnesium and its therapeutic uses: A review. Am J Med 1994 (96): 63-76.

 

11. Anand I, et al. Acute and chronic effects of propionyl-L-carnitine on the hemodynamics, exercise capacity, and hormones in patients with congestive heart failure. Cardiovasc Drugs Ther. Jul1998;12(3):291-9.
 

12. Mancini M et al. Controlled study on the therapeutic efficacy of propionyl-L-carnitine in patients with congestive heart failure. Arzneim Forsch 1992 (42): 1101-4

 

13. Pucciarelli G et al. The clinical and hemodynamic effects of propionyl-L-carnitine in the treatment of congestive heart failure. Clin Terr 1992 (141): 379-84.

 

14. Leuchtgens H. Crataegus Special Extract WS 1442 in NYHA II heart failure: A placebo controlled randomized double-blind study. Fortschr Med 1993 (111): 352-4.

 

15. Katz SD, et al. Decreased activity of the L-arginine-nitric oxide metabolic pathway in patients with congestive heart failure. Circulation. Apr1999;99(16):2113-7.
 

16. Bednarz B, Jaxa-Chamiec T, Gebalska J, Herbaczynska-Cedro K, Ceremuzynski L. L-arginine supplementation prolongs duration of exercise in congestive heart failure. Kardiol Pol. Apr2004;60(4):348-53.
 

17. Koifman B, et al. Improvement of cardiac performance by intravenous infusion of L-arginine in patients with moderate congestive heart failure. J Am Coll Cardiol. Nov1995;26(5):1251-6.

 

18. Jayasankar V et al. Local myocardial overexpression of growth hormone attenuates postinfarction remodeling and preserves cardiac function. Ann Thorac Surg. 2004 Jun;77(6):2122-9; discussion
 

19. Cicoira M et al. Growth hormone resistance in chronic heart failure and its therapeutic implications. J Card Fail. 2003 Jun;9(3):219-26. Review.

 

20. Dreifuss P, [Dilated cardiomyopathy and growth hormone] Z Kardiol. 2002 Dec;91(12):973-7. Review. German.
 

21. Napoli R et al. J Am Coll Cardiol. 2002 Jan 2;39(1):90-5. Growth hormone corrects vascular dysfunction in patients with chronic heart failure.
 

22. Fazio S et al. A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. N Engl J Med. 1996 Mar 28;334(13):809-14.

 

23. Suleiman MS et al. A loss of taurine and other amino acids from ventricles of patients undergoing bypass surgery. Br Heart J. 1993 Mar;69(3):241-5.            
 

24. Packer M. Potential role of potassium as a determinant of morbidity and mortality in patients with systemic hypertension and congestive heart failure. Am J Cardiol. Mar1990;65(10):45E-52E.

 

25. Lindeman RD. Hypokalemia: Causes, Consequences and Correction. Am J Med Sci. Aug 1976;272(1):5-17.
 

26. Francis GS. Interaction of the sympathetic nervous system and electrolytes in congestive heart failure. Am J Cardiol. Mar1990;65(10):24E-27E, 52E.
 

27. Chan AC. Vitamin E and atherosclerosis. J Nutr. 1998;128(10):1593-6.

 

28. Stephens NG, et al. Randomised controlled trial of vitamn E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet. 1996 Mar 23;347(9004):781-6.

 

29. Tsai PJ, Lu SC. Fish oil lowers plasma lipid concentrations and increases the susceptibility of low density lipoprotein to oxidative modification in healthy men. J Formos Med Assoc 1997 96(9): 718-26.

 

30. Morcos NC. Modulation of lipid profile by fish oil and garlic combination. J Natl Med Assoc 1997 89(10): 673078.

 

31. Oh-hashi K et al. Possible mechanisms for the differential effects of high linoleate safflower oil and high alpha-linolenate perilla oil diets on platelet-activating factor production by rat polymorphonuclear leukocytes. J Lipid Mediat Cell Signal. 1997 Dec;17(3):207-20

 

32. Life Extension eds., Disease Prevention and Treatment, 4th ed. Florida: Life Extension Media, 2003.